Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects

Sponsor
Novo Nordisk A/S
Study ID
NCT01619345
Phase
PHASE1
Status
Completed

Conditions

  • Diabetes
  • Healthy

Eligibility Criteria

Sex
MALE
Age
18 Years - 64 Years
Healthy Volunteers
Accepted

Interventions

  • semaglutide — DRUG
    Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.

Study Details

This trial is conducted in Europe. The aim of this trial is to investigate whether the volume of water administered with NN9924 affects the anatomical location (stomach or proximal small bowel) of tablet erosion.

Key Dates

Start date
Jun 30, 2012
Status verified
Feb 2015
Primary completion
Aug 31, 2012
Completion
Aug 31, 2012

Study Design

Enrollment
27 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Period 1: NN9924 with 50 mL water
  • Experimental: Period 2: NN9924 with 240 mL water

Primary Outcome Measure

Anatomical location (stomach or proximal small bowel) of tablet at complete tablet erosion (CTE) [ Time Frame: Assessed 0-4 hours post dose ]

Related Studies